Provide your input today and you will be helping to guide the critical future of inhibitor research.
By accessing this activity healthcare providers will increase their knowledge of the potential role of gene therapy to address challenges in current hemophilia treatment.
Investigators study early risk factors and prevention of cardiovascular disease in children and young adults with hemophilia.
The therapy is for people with severe and moderately severe hemophilia B.
The new vial size will reduce the reconstitution time that was needed to prepare multiple vials for a similar dose.
The therapy in trial is for the prophylactic treatment of individuals with hemophilia A or B with inhibitors.
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car